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PPARd Is an APC-Regulated Target of Nonsteroidal
Anti-Inflammatory Drugs
of COX-2 is elevated in human colorectal tumors (Eber-
hart et al., 1994; Sano et al., 1995), and inactivation of
the COX-2 gene in mice is associated with decreased
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However, other observations are difficult to reconcileJohns Hopkins University
Baltimore, Maryland 21231 with COX being the sole target of NSAIDs in the colon.
For example, NSAID derivatives that lack the ability to
inhibit COX have been shown to inhibit colon tumor
growth in vivo and in vitro (Piazza et al., 1995, 1997;Summary
Mahmoud et al., 1998; Reddy et al., 1999). Conversely,
colon cancer cells totally devoid of COX activity arePPARd was identified as a target of APC through the
growth inhibited as effectively as cells producing COXanalysis of global gene expression profiles in human
(Hanif et al., 1996; Elder et al., 1997). Likewise, COX-1colorectal cancer (CRC) cells. PPARd expression was
and COX-2 null mouse embryo fibroblast cells remainelevated in CRCs and repressed by APC in CRC
sensitive to the antiproliferative and antineoplastic ef-cells. This repression was mediated by b-catenin/Tcf-
fects of NSAIDs (Zhang et al., 1999). In those colon4-responsive elements in the PPARd promotor. The
cancer cells producing COX, COX-produced prosta-ability of PPARs to bind eicosanoids suggested that
glandins cannot rescue cells from NSAID-associatedPPARd might be a target of chemopreventive non-
growth arrest in vivo or in vitro (Narisawa et al., 1984;steroidal anti-inflammatory drugs (NSAIDs). Reporters
Hanif et al., 1996; Chan et al., 1998). The concentrationcontaining PPARd-responsive elements were repressed
of NSAIDs that inhibit growth is 10 to 100 times higherby the NSAID sulindac. Furthermore, sulindac was able
than that required to inhibit COX activity, suggesting theto disrupt the ability of PPARd to bind its recognition
existence of additional cellular targets (Hanif et al., 1996;sequences. These findings suggest that NSAIDs inhibit
Ahnen, 1998; Charalambous et al., 1998; Simmons ettumorigenesis through inhibition of PPARd, the gene
al., 1999). Finally, many studies have demonstrated thatfor which is normally regulated by APC.
the COX-2 protein is elevated in the neoplastic epithelial
cells of human tumors (Eberhart et al., 1994; Sano etIntroduction
al., 1995), while COX-2 expression in mouse intestinal
tumors is confined to nonneoplastic stromal cells (OshimaColorectal cancer (CRC) is the second leading cause of
et al., 1996; Shattuck-Brandt et al., 1999). Thus, thecancer deaths in the United States. Recent advances
mouse and human COX-2 proteins are located withinin the understanding of CRC have raised expectations
disparate cellular populations of the colon, yet tumori-that this growing knowledge might lead to improved
genesis in both species is prevented by the samecancer prevention. In this regard, the identification of
NSAIDs. This suggests either that it is coincidental thatgenetic alterations that underlie the initiation of colo-
the same agents can exert chemopreventive effects inrectal tumors and of drugs which can prevent colorectal
mouse and human, or that other targets of NSAIDs,tumors show particular promise. Here, we suggest a
common to the neoplastic cells of both species, mightmolecular basis for the convergence of these two here-
exist and provide a link to the molecular pathogenesistofore separate lines of investigation.
described below.A growing body of evidence has shown that nonsteroi-
Molecular genetic studies have identified a series ofdal anti-inflammatory drugs (NSAIDs) can suppress co-
genetic alterations associated with the development oflorectal tumorigenesis in both humans and rodents (re-
benign tumors (adenomas) and their progression to ma-viewed in Smalley and DuBois, 1997; Thun, 1997). In
lignant disease (carcinomas) (reviewed in Kinzler andthe general population, epidemiological studies have
Vogelstein, 1996). In terms of prevention, the alterationsdocumented a decreased risk of CRC deaths associated
that occur early in this process are of most interest.with use of the NSAID aspirin. In individuals with familial
Inactivating mutations of the APC tumor suppressoradenomatous polyposis (FAP), an inherited predisposi-
pathway occur early and are found in most colorectaltion to multiple colorectal polyps, the NSAID sulindac
adenomas and carcinomas. Moreover, inherited muta-can reduce both the size and number of colorectal tu-
tions of APC cause FAP, characterized by the develop-mors. Likewise, sulindac and other NSAIDs have proven
ment of hundreds to thousands of colorectal adenomas.to be effective in prevention of intestinal tumorigenesis
Several studies have suggested that APC's associationin mouse models of FAP. The molecular basis for these
with b-catenin (Rubinfeld et al., 1993; Su et al., 1993)striking chemopreventive effects has been attributed to
might be critical to its tumor-suppressive effects. In theinhibition of cyclooxygenases (COX) and the resulting
colon, b-catenin binds to the Tcf-4 transcription factor,decrease in prostaglandin production (reviewed in Pres-
providing a domain that activates genes containing Tcf-cott and White, 1996). Consistent with this, expression
4-binding sites in their regulatory regions (Behrens et
al., 1996; Molenaar et al., 1996). Wild-type APC can
promote the degradation of b-catenin (Munemitsu et al.,³ To whom correspondence should be addressed (e-mail: kinzlke@
welchlink.welch.jhu.edu). 1995) and inhibit b-catenin/Tcf-4 regulated transcription
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(CRT), while disease-associated APC mutants are defi-
cient in this ability (Korinek et al., 1997; Morin et al.,
1997). In tumors lacking APC mutations, oncogenic mu-
tations of b-catenin can lead to increased CRT (Morin
et al., 1997; Rubinfeld et al., 1997).
The targets of this increased CRT are therefore likely
to provide insights into APC's suppressive effects. We
have recently used SAGE technology to analyze changes
in gene expression following inhibition of CRT by APC
in human CRC cells and identified the c-myc oncogene
as a direct target of CRT (He et al., 1998a). However,
like many other critical regulators of cell growth, APC
is likely to exert its effects through several effectors.
Here, we report the identification of another target of
the APC pathway, peroxisome proliferator-activated re-
ceptor d (PPARd; a.k.a. PPARb, NUC1, and FAAR)
(Schmidt et al., 1992; Amri et al., 1995; Jow and Mukh-
erjee, 1995), which provides a link between NSAID-medi-
ated chemoprevention and the genetic alterations iden-
tified in colorectal tumors.
PPARd belongs to the nuclear receptor superfamily,
which includes the steroid hormone, thyroid hormone,
retinoid, and PPAR subfamilies as well as a growing Figure 1. Expression of PPARd in Human CRC Cells
number of orphan receptors (Kastner et al., 1995; (A) Decreased expression of PPARd following induction of APC in
CRC cells. Expression of APC (HT29-APC) or b-galactosidaseMangelsdorf et al., 1995; Lemberger et al., 1996). The
(HT29-GAL) was induced with (110 mM) ZnCl2 for the indicated timesPPAR subfamily comprises at least three distinct sub-
in HT29 CRC cells containing the respective genes under the controltypes found in vertebrate species: PPARa, PPARd, and
of a modified metallothionein promotor. Total RNA (10 mg) was iso-PPARg. The nuclear receptor family members function
lated and analyzed by Northern blot analysis with probes specific
as ligand-dependent sequence-specific activators of for PPARd and PPARg.
transcription (Mangelsdorf et al., 1995; Lemberger et al., (B) Increased expression of PPARd in primary CRCs. Northern blot
analyses with probes specific to PPARd and PPARg were performed1996). We found that the NSAIDs sulindac and indo-
on total RNA (10 mg) isolated from matched primary CRCs (C) andmethacin could mimic the effects of APC by downregu-
normal colon epithelium (N) removed from four different patients.lating the transcriptional activity of PPARd. This inhibi-
(C) Expression of PPARd in CRCs is dependent on Tcf-4-mediatedtion appeared to be due to disruption of the DNA binding
transcription. CRC cells with increased b-catenin/Tcf-4-mediated
ability of PPARd/RXR heterodimers. These observations transcription due to either APC (SW480, DLD1) or b-catenin
demonstrate that APC and NSAIDs inhibit a mutual tar- (HCT116) mutations were either mock infected (Con) or infected with
adenovirus expressing GFP (GFP) or a dominant-negative mutant ofget, PPARd, thereby providing a link between the genetic
Tcf-4 (dnTcf). Total RNA (10 mg) was isolated and analyzed by North-alterations underlying tumor development and cancer
ern blot analysis with probes specific for PPARd and PPARg.chemoprevention.
Results PPARg was not affected by expression of APC, and the
other known PPAR subfamily member, PPARa, was not
expressed at detectable levels (Figure 1A and data notAPC Represses PPARd Expression
The effects of APC on gene expression were explored shown). The ability of APC to repress PPARd expression
suggested that expression of PPARd should be elevatedusing SAGE as previously reported (He et al., 1998a). In
brief, gene expression was examined in a human CRC in primary CRCs, where CRT is often increased by muta-
tions in APC or b-catenin. Northern blot analysis ofcell line with inducible APC (HT29-APC) and a control
cell line with an inducible lacZ gene (HT29-b-gal) 9 hr PPAR expression in CRCs and normal colorectal mu-
cosa revealed a marked increase in PPARd expressionafter induction. SAGE analysis of 55,233 and 59,752 tags
from APC-expressing and control cells, respectively, led in each of four cancers studied (Figure 1B). In contrast,
there was no increase in PPARg expression in the can-to the identification of 14,346 different transcripts, the
majority of which were not differentially expressed. Be- cers of these patients (Figure 1B).
cause biochemical studies have indicated that APC di-
rectly represses CRT, we focused on the repressed APC Inhibits CRT of the PPARd Gene
To explore the basis for the repression of PPARd, wetranscripts. One of the most highly repressed tags corre-
sponded to PPARd (24 tags in HT29-b-gal versus 5 tags isolated and sequenced a 3.1 kb genomic region up-
stream of the PPARd transcription start site (GenBankin HT29-APC).
To confirm the SAGE data, we performed Northern accession #AF187850) and used it to analyze APC re-
sponsiveness (Figure 2). A luciferase reporter constructblot analysis of RNA from HT29-APC and HT29b-gal
cells using PPAR probes (Figure 1A). Repression of containing this fragment (BE) upstream of a minimal
promotor was markedly repressed by APC expressionPPARd was evident as early as 3 hr after APC induction,
whereas no change was detectable in HT29 b-gal cells (Figures 2A and 2B). Analysis of nested deletions and pro-
motor fragments identified two APC-responsive frag-even 9 hr after induction. In contrast, expression of
PPARd and Chemoprevention
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Figure 2. APC Regulates PPARd Expression
through CRT
(A) PPARd promotor. A restriction map of the
3.1 kb region upstream of the first exon of
PPARd is shown. Restriction fragments BE,
NE, HE, DE, BN, NH, HD, and NP were used
to construct reporters for measuring APC and
b-catenin responsiveness. Filled boxes rep-
resent potential Tcf-4-binding sites, and open
boxes represent the same sites engineered to
contain mutations that abolish Tcf-4 binding.
mNP represents fragment NP with both po-
tential Tcf-4-binding sites mutated. TRE1 and
TRE2 contain four repeats of the two Tcf-
4-binding sites, respectively. mTRE1 and
mTRE2 are mutant forms of TRE1 and TRE2.
(B) The PPARd promotor is repressed by APC
and dnTcf. SW480 CRC cells were trans-
fected with the indicated PPARd promotor
luciferase reporters (0.4 mg), with a b-galac-
tosidase expression vector (0.2 mg pCMVb),
and with 1.0 mg of either a control (Vector),
APC, or dnTcf expression vector. Luciferase
activity is reported relative to the vector con-
trol after normalizing for transfection effi-
ciency through b-galactosidase activity. Bars
represent the means of three independent
replicates with error bars representing the un-
biased standard deviations.
(C) APC and dnTcf responsiveness is medi-
ated by two putative Tcf-4-binding sites.
PPARd promotor fragments with intact and
mutated Tcf-4-binding sites were tested for
APC and dnTcf-4 responsiveness as de-
scribed in (B). Bars represent the means of
three independent replicates, with error bars
representing the unbiased standard devia-
tions.
(D) b-catenin transactivation maps to the
same promotor regions mediating APC and
dnTcf responsiveness. 293 cells were trans-
fected with the indicated PPARd promotor
luciferase reporters (0.4 mg), with a b-galactosidase expression vector (0.2 mg pCMVb), and with 1.0 mg of either a no insert control (Vector)
or an oncogenic b-catenin (b-catenin) expression vector. Luciferase activity was reported as described for (B). Bars represent the means of
three independent replicates, with error bars representing the unbiased standard deviations.
(E) Putative Tcf-4-binding sites in the PPARd promotor bind Tcf-4. GEMSA was performed using 32P-labeled probes containing either putative
Tcf-4-binding sites TRE1 or TRE2. GEMSA was performed in the presence of a GST fusion protein containing the Tcf-4 DNA-binding domain
as indicated. Wild-type (wt) or mutant (mut) competitors corresponding to the Tcf-4-binding sites were used as indicated.
ments (fragment NH and HD, Figures 2A and 2B). The APC responsiveness and the ability of a dominant-nega-
tive Tcf-4 (dnTcf) expression vector to inhibit transcrip-sequence of these fragments revealed two putative Tcf-
4-binding sites, one (TRE1) located 1543 bp upstream tional activity (Figures 2B and 2C). As with APC respon-
siveness, the b-catenin transactivation and the dnTcfof the PPARd transcription start site in fragment NH and
the other (TRE2) located 759 bp upstream in fragment repression were abrogated by mutation of the putative
Tcf-4-binding sites (Figures 2C and 2D). The ability ofHD. A fragment spanning these two sites conferred
marked APC repression, which was completely abro- Tcf-4 to directly bind to the PPARd TRE sites was dem-
onstrated by gel electrophoresis mobility shift assaysgated by disruption of the putative Tcf-4-binding sites
(NP versus mNP, Figure 2C). Moreover, either of the (GEMSA). Both putative binding sites demonstrated sig-
nificant Tcf-4 binding, which was inhibited by their cog-putative Tcf-4-binding sites in isolation could confer
APC responsiveness in a sequence-specific manner nate wild-type binding sequences but not by their mu-
tant counterparts (Figure 2E).(TRE1 versus mTRE1, and TRE2 versus mTRE2 in Fig-
ure 2C). The above results suggested that APC repressed
PPARd expression by interfering with CRT and that alter-As noted above, an obvious basis for the APC respon-
siveness of PPARd would be inhibition of CRT. Consis- ations in this pathway could lead to increased expres-
sion of PPARd in CRCs. To further evaluate the generalitytent with this, there was a perfect concordance between
the ability of APC to repress PPARd promotor frag- of this pathway, we examined the ability of dnTcf to
interfere with PPARd expression in other human CRCments (Figures 2B and 2C) and the ability of oncogenic
b-catenin to induce transcriptional activity (Figure 2D). cell lines. Like the HT29 cells in which PPARd expression
was first identified (Figure 1A), SW480 and DLD1 cellsLikewise, there was a perfect concordance between
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contain inactivating mutations of APC. HCT116 cells reporter even in the presence of cPGI (Figure 3F). In
have an activating mutation of b-catenin. As expected contrast, expression of PPARg did not activate the DRE
from the study of primary tumors (Figure 1B), PPARd reporter (Figure 3E) but did activate the ACO reporter
expression was detected in all the lines (Figure 1C). that was enhanced by BRL 49653 (Figure 3F).
Moreover, PPARd expression was inhibited in each line
by infection with an adenovirus containing a dnTcf ex-
pression cassette but not by a control adenovirus con- PPARd Function Is Regulated by the APC/b-Catenin/
taining a GFP expression cassette (Figure 1C). In con- Tcf-4 Pathway
trast, PPARg expression was barely detectable in The above findings suggested that PPARd activity was
SW480 cells, and dnTcf had no effect on PPARg expres- regulated by APC/b-catenin/Tcf-4 pathway at the tran-
sion in any of the lines tested. scriptional level. To address the functional conse-
quences of this transcriptional regulation in CRC cells,
Definition of PPARd-Responsive Elements we used the PPARd-specific reporters described above.
To explore the functional significance of PPARd repres- Transfection of APC into a human CRC cell line resulted
sion, we developed reporters for PPARd function. Al- in downregulation of the PPARd reporter DRE but had no
though downstream targets of PPARd are unknown, effect on the PPARa/g-responsive reporter ACO (Figure
studies of other PPAR family members have defined a 4A). The lack of any effect on PPARa/g demonstrated
prototypic response element. Maximum DNA binding the specificity of this inhibition and made it unlikely that
and activation are achieved through heterodimerization the effects were due to nonspecific toxicity of a tumor
between a PPAR protein and RXR (Gearing et al., 1993).
suppressor. Transfection of a dnTcf-4 expression vector
Accordingly, the prototypic PPAR response element
also specifically repressed the PPARd reporter but notACO from the acyl-CoA oxidase gene promotor contains
the PPARa/g reporter. To further eliminate the possibilitytwo copies of the core binding sequence AGGTCA
of nonspecific toxic effects, we tested b-catenin's abilityseparated by one base pair (Tugwood et al., 1992;
to positively regulate PPARd activity. Expression of on-Mangelsdorf et al., 1995; Lemberger et al., 1996; Juge-
cogenic b-catenin mutants activated the PPARd re-Aubry et al., 1997). PPARa and PPARg bind this consen-
porter but did not activate the PPARa/g reporter (Fig-sus efficiently, whereas PPARd does not (see below).
ure 4B).To define a PPARd-responsive element, we performed
in vitro binding site selection for both PPARd and RXRa.
Analysis of 28 binding sites selected with a RXRa GST
NSAIDs Suppress PPARd Activityfusion protein identified (A/G)GGTCA as the core con-
Suppression of colorectal tumorigenesis by NSAIDssensus for RXR (Figure 3A). Analysis of 20 sites selected
suggested that these compounds may be linked to thewith a PPARd GST fusion protein revealed a novel bind-
genetic alterations that drive tumorigenesis. The identifi-ing consensus (CGCTCAC), which was distinct from the
cation of PPARd as a target of the APC tumor suppressorpreviously defined PPARa/g consensus (Figure 3B).
pathway suggested a specific link. Both precursors andThe combination of the PPARd and RXRa consensus
products involved in eicosanoid metabolism have beensequences should form a PPARd-binding element in
shown to be ligands for PPARs (Keller et al., 1993; Yuvitro and a PPARd-responsive element in vivo. We
et al., 1995; Forman et al., 1997; Kliewer et al., 1997).generated a putative PPARd-responsive element (DRE,
59-CGCTCACAGGTCA-39) by joining the PPARd- and The ability of NSAIDs to perturb eicosanoid metabolism
RXRa-binding sites. GEMSA analysis of DRE revealed suggested that PPARs may be an ultimate target of
binding to PPARd GST fusion protein but not to PPARa NSAIDs in suppressing tumorigenesis (Prescott and
or PPARg GST fusion proteins (Figure 3C). In contrast, White, 1996), and the above findings suggest that PPARd
the prototypic PPAR-responsive element ACO (59-AGG could be a specific target. To explore this possibility,
ACAAAGGTCA-39) bound PPARa and PPARg but not we tested the effects of the NSAID sulindac on PPARd
PPARd GST fusion proteins (Figure 3C). RXRa GST fu- function. As noted in the Introduction, sulindac has been
sion protein demonstrated weaker binding to both re- shown to suppress intestinal tumorigenesis in humans
sponsive elements. To further test the specificity of and mice. In culture, sulindac sulfide, the active metabo-
these elements, we performed GEMSA analysis with in lite of sulindac, has been shown to induce apoptosis in
vitro translated PPARd/RARa and PPARg/RARa hetero- CRC cells (Piazza et al., 1995; Shiff et al., 1995; Hanif
dimers in the presence or absence of ligand stimulation. et al., 1996; Chan et al., 1998). Sulindac sulfide treatment
Under the conditions used, binding of PPARd/RXRa and
resulted in a dose-dependent repression of PPARd ac-
PPARg/RXRa heterodimers to their cognate elements
tivity in CRC cells, as assessed with the DRE reportercould not be detected in the absence of ligand. However,
(Figure 4C). A greater than 2-fold repression was ob-PPARd/RXRa binding to DRE was markedly induced by
served at low concentrations of sulindac sulfide, and athe PPARd ligand cPGI, and PPARg/RXRa binding to
greater than 10-fold reduction was noted at levels ofACO was induced by the PPARg ligand BRL49653 (Fig-
sulindac sulfide that induced substantial degrees ofure 3D). In contrast, PPARg/RXRa heterodimers did not
apoptosis in these cells (Figures 4C and 5D). In contrast,bind DRE in the presence of BRL49653 nor did PPARd/
sulindac sulfide had only a modest effect (less thanRXRa bind ACO in the presence of cPGI. To test the
25% repression at the highest concentration tested) onspecificity of these response elements in cells, we con-
PPARa/g activity, assessed with the ACO reporter (Fig-structed luciferase reporters containing either the DRE
ure 4C). A similar dose-dependent suppression ofor ACO elements. Transfection of 293 cells with PPARd
PPARd was observed with indomethacin, another NSAIDresulted in activation of the DRE reporter that was en-
hanced by cPGI (Figure 3E) but did not activate the ACO (Figure 4C).
PPARd and Chemoprevention
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Figure 3. Development of a PPARd-Specific Reporter
(A) RXRa consensus binding site. PCR products of a randomized oligonucleotide template that bound a GST fusion protein containing the
DNA-binding domain of RXRa were selected, cloned, and sequenced. The sequences of 28 clones are shown, manually aligned to derive the
consensus binding sequence indicated at the bottom.
(B) PPARd consensus binding site. PCR products of a randomized oligonucleotide template that bound a GST fusion protein containing the
DNA-binding domain of PPARd were selected, cloned, and sequenced. The sequences of 20 clones are shown, manually aligned to derive
the consensus binding sequence indicated at the bottom.
(C) Binding specificity of PPARa, PPARd, and PPARg. Oligonucleotides containing the indicated binding elements (DRE or ACO) were 32P-labeled
and incubated with GST fusion proteins containing either the PPARa, PPARd, PPARg, RXRa, or no DNA binding domain (2). DNA binding
was assessed by GEMSA, where ªProbeº indicates the unbound probe and ªShiftedº indicates bound probe.
(D) Binding specificity of PPARd/RXRa and PPARg/RXRa heterodimers. Oligonucleotides containing the indicated binding elements (DRE or
ACO) were 32P-labeled and incubated with in vitro translated PPARd, PPARg, and RXRa as indicated. Bindings were supplemented with PPARd
ligand cPGI (10 mM) or PPARg ligand BRL 49653 (10 mM) as indicated. DNA binding was assessed by GEMSA, where ªProbeº indicates the
unbound probe and ªShiftedº indicates bound probe.
(E) DRE confers PPARd but not PPARg responsiveness. 293 cells were transfected with DRE luciferase reporter (0.3 mg), a b-galactosidase
expression vector (0.2 mg pCMVb), and with 1.0 mg of either empty vector (Control), PPARd, or PPARg expression vectors. Where indicated,
cells were treated with the PPARd ligand cPGI (20 mM) or the PPARg ligand BRL 49653 (20 mM). Luciferase activity was reported as relative
luciferase activity after correction for transfection efficiency using b-galactosidase activity. Bars represent the means of three independent
replicates with the error bars representing the unbiased standard deviations.
(F) ACO confers PPARg but not PPARd responsiveness. The same as in (E) except an ACO luciferase reporter was used.
Cell
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Expression of PPARd Partially Rescues Sulindac
Sulfide±Induced Apoptosis
If suppression of PPARd activity were contributing to
sulindac-induced apoptosis, overexpression of PPARd
might be expected to protect against sulindac sulfide±
induced apoptosis. We constructed an adenovirus (Ad-
PPARd) expressing PPARd and a green fluorescent pro-
tein (GFP) marker using AdEasy technology (He et al.,
1998b). The ability of AdPPARd to suppress sulindac
sulfide±induced apoptosis was compared to that of
AdGFP, which contained only the GFP marker gene.
AdPPARd produced nearly a 5-fold decrease in apopto-
sis in HCT116 cells treated with 100 or 125 mM sulindac
sulfide (Figures 5A±5D). Similar results were obtained
with the SW480 cell line (Figure 5D). However, the sup-
pression of apoptosis could be overridden at higher
concentrations of sulindac sulfide (150 mM, Figure 5D).
The results were further confirmed and extended by the
ability of AdPPARd to rescue inhibition of clonal cell
growth by sulindac sulfide. Treatment of cells with sulin-
dac sulfide resulted in a greater than 4-fold decrease in
the number of colonies (Figure 5E). At 100 or 125 mM
sulindac sulfide but not higher doses, this decrease
could be completely rescued by infection with Ad-
PPARd, which actually resulted in a slightly increased
number (z15%) of colonies. In contrast, the APC target
and prototypic oncogene c-myc could not rescue the
sulindac-mediated inhibition of clonal growth.
Sulindac Sulfide Disrupts the DNA Binding Ability
of PPARd/RXRa Heterodimers
To determine whether sulindac could inhibit the tran-
scription of PPARd like APC, we examined expression
of PPARd following sulindac sulfide treatment. Concen-
Figure 4. PPARd Activity Is Regulated by APC, b-Catenin, and Sul- trations of sulindac sulfide that resulted in suppression
indac of PPARd activity and apoptosis had no effect on the
(A) APC and dnTcf specifically repress PPARd activity. PPARd and level of PPARd transcripts, excluding this possibility
PPARg activity was assessed with the DRE and ACO luciferase (Figure 6A). Because PPARs can bind eicosanoids (Kel-
reporters, respectively. SW480 CRC cells were transfected with
ler et al., 1993; Yu et al., 1995; Forman et al., 1997;the indicated luciferase reporters (0.4 mg of DRE or ACO), with a
Kliewer et al., 1997), the effects of NSAIDs on PPARdb-galactosidase expression vector (0.2 mg pCMVb), and with 1.0 mg of
either a control (Vector), APC, or dnTcf expression vector. Luciferase could be due to their ability to perturb eicosanoid metab-
activity was calculated as described in Figure 2. Bars represent the olism. However, several studies (see Discussion) have
means of three independent replicates with the error bars being the suggested that the chemopreventive effects of NSAIDs
unbiased standard deviations.
are not simply related to their ability to suppress prosta-(B) b-catenin expression increases PPARd activity. The 293 human
glandin synthesis. We therefore considered the possibil-cell line was transfected with the indicated luciferase reporters (0.4
ity that NSAIDs directly inhibit PPARd activity. This no-mg of DRE or ACO), with a b-galactosidase expression vector (0.2
mg pCMVb), and with 0.8 mg of either a no insert control (Vector) or tion was supported by the ability of some NSAIDs to
an oncogenic b-catenin expression vector. activate PPARa/g (Lehmann et al., 1997) and of indo-
(C) Sulindac and indomethacin specifically repress PPARd activity.
methacin to alter the ligand responsiveness of TetR/PPARd and PPARg activity was assessed as transcriptional activity
PPARd fusion proteins (Yu et al., 1995). We tested theof the DRE and ACO luciferase reporters, respectively. HCT116 and
ability of sulindac to inhibit cPGI-stimulated PPARd/SW480 CRC cells were transfected with the indicated luciferase
reporters (1.0 mg of DRE or ACO) and with a b-galactosidase expres- RXRa heterodimer DNA binding activity in vitro. Sulindac
sion vector (0.2 mg of pCMVb). Cells were allowed to recover for 20 sulfide was able to inhibit binding of PPARd/RXRa het-
hr after transfection and then treated for 10 hr with the indicated erodimers to the DRE element (Figure 6B). Binding to DRE
concentrations (mM) of sulindac sulfide or indomethacin. Luciferase
was also inhibited by the NSAID indomethacin and, atactivity was reported relative to the control (0) after normalizing for
higher concentrations, the sulindac sulfide±related com-transfection efficiency.
pound sulindac sulfone (Figure 6B). The relative concen-
trations of sulindac sulfide, indomethacin, and sulindac
sulfone required to inhibit binding to DRE were roughly
concordant with the concentrations required to induce
apoptosis in CRC cells, with sulindac sulfide being the
most potent and sulindac sulfone the least (Figures 5D
PPARd and Chemoprevention
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Figure 5. PPARd Can Protect Colon Cancer Cells from Sulindac-Induced Apoptosis
(A±D) PPARd inhibits sulindac sulfide±induced apoptosis. HCT116 and SW480 cells were either mock infected (Uninfected) or infected with
adenovirus expressing GFP (AdGFP) or PPARd (AdPPARd). Twenty hours after infection, cells were treated for 42 hr with sulindac sulfide.
Apoptosis was assessed by the presence of apoptotic nuclei (condensation and fragmentation) after Hoechst 33258 staining. (A±C) Fluorescence
microscopy of uninfected (A), AdGFP (B), or AdPPARd (C) infected HCT116 cells treated with 125 mM of sulindac sulfide. (D) Bars represent
the fraction of apoptotic nuclei after treatment with the indicated adenoviruses and concentration of sulindac sulfide (mM).
(E) PPARd rescues sulindac sulfide inhibition of clonal growth. Cells were infected with the indicated adenovirus, treated with the indicated
concentrations of sulindac sulfide, and plated. Clonal growth was scored as colony formation after 6 days. Colonies were visualized by staining
with Crystal Violet (upper panel) and enumerated (lower panel).
and 6B; data not shown). None of these drugs had any to increased transcription of growth-promoting genes.
Accordingly, restoration of APC function to CRC cellseffect on BRL49653-stimulated binding of PPARg/RXRa
heterodimers in an analogous assay performed with the with defective APC function results in growth suppres-
sion and apoptosis (Morin et al., 1996). The genes thatACO element (Figure 6C).
have been postulated to mediate the growth-promoting
effects of b-catenin/Tcf-4 activity include those en-Discussion
coded by the c-myc oncogene (He et al., 1998a), the
cyclin D1 gene (Tetsu and McCormick, 1999), and othersThe above results demonstrate that PPARd is a target
(WISP, c-jun, and fra-1) (Pennica et al., 1998; Mann etof both APC and NSAIDs and suggest a model of how
al., 1999). The present findings suggest that PPARdAPC and NSAIDs operate to suppress intestinal tumori-
represents a b-catenin/Tcf-4 target with particular impor-genesis (Figure 7). In most CRCs, inactivating mutations
tance for chemoprevention. Whereas APC or b-cateninof APC lead to elevated levels of CRT (Korinek et al.,
mutations can result in increased PPARd activity, NSAIDs1997; Morin et al., 1997). In rare CRCs without APC
can compensate for this defect by suppressing PPARdmutations, b-catenin mutations that render it resistant to
activity and promoting apoptosis. This suppression ofAPC-mediated degradation result in elevated b-catenin/
PPARd is mediated in part by the ability of some NSAIDsTcf-4-mediated transcription (Morin et al., 1997). In ei-
ther case, this increased b-catenin/Tcf-4 activity leads to directly inhibit the DNA binding activity of PPARd. In
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Figure 7. Unified Model for APC- and NSAID-Mediated Suppression
of CRC
Elements indicated in blue have been shown to have a tumor-sup-
pressive effect, whereas elements in red have been shown to pro-
mote tumor formation. The effects of items in boxes have been
demonstrated by genetic alterations. LOX, 5-lipoxygenase; sPLA2,
secretory phospholipase 2; and COX, cyclooxygenase.
underlie the initiation of these tumors and to the ability
of NSAIDs to counterbalance the consequences of these
genetic defects. Second, although NSAID functions
have been linked to their inhibition of COX activity and
the resulting inhibition of prostaglandin synthesis, sev-
eral studies have suggested that the chemopreventive
and apoptosis-inducing activities of NSAIDs are not en-
tirely related to the inhibition of COX or to the decreased
levels of prostaglandins (see Introduction). These results
may be explained by the ability of NSAIDs to directly
inhibit PPARd. Indeed, the sulindac derivative sulindac
sulfone, which is devoid of COX inhibitory activity, hasFigure 6. Mechanism of Suppression of PPARd by NSAIDs
apoptotic activity in vitro and chemopreventive activity(A) NSAIDs do not affect PPARd, PPARg, or RXRa expression.
in vivo and has been proposed as a chemopreventiveHCT116 and SW480 cells were treated with the indicated concentra-
tion (mM) of sulindac sulfide for 36 hr, and RNA was isolated. North- agent that lacks the toxicity associated with traditional
ern blot analysis was performed on 10 mg of total RNA with a probe NSAIDs (Piazza et al., 1995, 1997; Mahmoud et al., 1998).
specific for PPARd, PPARg, or RXRa. Sulindac sulfone inhibited PPARd activity, albeit at
(B) NSAIDs suppress PPARd DNA binding. The DRE-binding element
higher concentrations than that required for sulindacwas 32P-labeled and incubated with no lysate (Probe only) or in vitro
sulfide, consistent with its reduced chemopreventivetranslated PPARd (d), RXRa (RXRa), or both (d 1 RXRa). PPARd 1
and apoptosis-promoting activity. Third, recent studiesRXRa 1 cPGI (10 mM) was included in all lysates treated with the
indicated NSAIDs. DNA binding was assessed by GEMSA, where have demonstrated that PPARg agonists promote intes-
ªProbeº indicates the unbound probe and ªShiftedº indicates bound tinal tumorigenesis in the Min mouse (Lefebvre et al.,
probe. 1998; Saez et al., 1998), while the same agonists inhibit
(C) NSAIDs do not suppress PPARg DNA binding. The ACO-binding
the growth of human CRC cells (Brockman et al., 1998;element was 32P-labeled and incubated with no lysate (Probe only)
Sarraf et al., 1998). Although the conclusions of theseor in vitro translated PPARg (g), RXRa (RXRa), or both (g 1 RXRa).
studies were contradictory, they clearly demonstratedPPARg 1 RXRa 1 BRL 49653 (10 mM) was included in all lysates
treated with the indicated NSAIDs. DNA binding was assessed by the ability of PPAR ligands to modify intestinal tumor
GEMSA, where ªProbeº indicates the unbound probe and ªShiftedº growth. A role for PPARs in intestinal tumorigenesis is
indicates bound probe. further suggested by the recent identification of loss-
of-function mutations in one allele of PPARg in 4 of
55 sporadic CRCs (Sarraf et al., 1999). However, unlikeaddition, because fatty acids and eicosanoids can act
as ligands and modifiers of PPAR activity (Keller et al., PPARd, neither PPARg nor PPARa is a target of the
APC/b-catenin pathway. Whereas PPARd is increased1993; Yu et al., 1995; Prescott and White, 1996; Forman
et al., 1997; Kliewer et al., 1997), PPARd activity might in expression in cancers, downregulated by APC, and
upregulated by b-catenin, PPARg and PPARa do notbe repressed by the NSAID-mediated changes in eico-
sanoid metabolism. display these properties. Fourth, the ability of COX2
expression to modulate apoptosis (Tsujii and Dubois,The above model can help explain several features of
NSAID-mediated chemoprevention. First, the effective- 1995) and intestinal tumorigenesis (Oshima et al., 1996)
may be partially related to its ability to alter the spectrumness of some NSAIDs in the prevention of colorectal
adenomas can now be linked to genetic defects that of ligands for PPARd and other PPARs. In this regard,
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Constructions of PPARd Promotor Reportersit is interesting to note that the PPARd ligand cPGI can
Three independent BAC clones containing the PPARd promotorpartially rescue infertility resulting from COX-2 defi-
sequence were obtained by screening a BAC library (Research Ge-ciency (Lim et al., 1999). Finally, the ability of dietary
netics). For the construction of PPARd promotor reporters, corre-
fatty acids and secreted phospholipases to modify the sponding restriction fragments (illustrated in Figure 2A) were sub-
spectrum of PPARd ligands and thus alter PPARd activity cloned into pBV-Luc. The mNP reporter was constructed by cloning
a PCR product into pBV-Luc, whereas p4XTRE1-Luc, p4XmTRE1-could account for their ability to affect CRC risk (Willett
Luc, p4XTRE2-Luc, and p4XmTRE2-Luc were constructed from oli-et al., 1990; Dietrich et al., 1993; MacPhee et al., 1995;
gonucleotides. Details of construction and oligonucleotide se-Vanden Heuvel, 1999).
quences are available upon request or at www.coloncancer.org/In addition to explaining several features of NSAID-
ppar.htm.
mediated chemoprevention, our observations may have
important ramifications for the development of chemo- Reporter Assays
preventive agents. In particular, it is conceivable that Reporter plasmid, effector plasmid, and b-gal control plasmid were
transfected into cells using LipofectAmine (Life Technologies).the development of drugs that specifically target PPARd
Twenty-four hours after transfection, cells were lysed and collectedmight lead to more efficacious and less toxic means for
for assays of luciferase activity using Promega's Luciferase AssayCRC chemoprevention.
System.
Experimental Procedures In Vitro Transcription and Translation Assays
The full-length proteins of PPARd, PPARg, and RXRa were gener-
Cell Lines and Chemicals ated by in vitro transcription-coupled translation of PCR products
Human CRC cells (HT29, HCT116, SW480, and DLD1) and embryonic using the TNT T7 Quick-Coupled Transcription/Translation System
kidney cells (293) were obtained from ATCC (Manassas, VA). (Promega). PCR primer sequences are available upon request or at
BRL49653 and cPGI were purchased from American Radiolabeled www.coloncancer.org/ppar.htm.
Chemicals and Cayman Chemical Company, respectively. Sulindac
derivatives and indomethacin were purchased from BIOMOL. Un- Generation of Recombinant Adenovirus Expressing PPARd
less otherwise indicated, all chemicals were purchased from Sigma or c-Myc
(St. Louis, MO). A PCR product of human PPARd was cloned into pCMV-HAHA
and verified by sequencing. This expression cassette was used
to generate recombinant adenovirus using the AdEasy system asIn Vitro DNA-Binding Site Selection for PPARd and RXRa
previously described (He et al., 1998b). Additional details of theGST fusion proteins containing the N-terminal DNA-binding domains
construction are available upon request or at www.coloncancer.org/of human PPARd and RXRa were constructed by PCR amplifying
ppar.htm. AdMyc was generated in a similar fashion and was a giftcodons 1±249 of PPARd and 1±224 of RXRa and cloning them into
of H. Hermeking.pGEX-2TK vector. As controls, GST fusion proteins containing the
DNA-binding domains of human PPARa (aa 1±249) and PPARg (aa
Acknowledgments1±248) were also constructed. To identify the potential consensus
DNA sequence motifs recognized by PPARd and RXRa, a previously
We thank Carlo Rago, Christopher Torrance, Victor Velculescu,described in vitro site selection procedure was utilized (Zawel et
Leigh Zawel, Lin Zhang, and Wei Zhou for their help and advice andal., 1998). Selected PCR products were cloned in to pZero2.1, tested
Heiko Hermeking for providing the AdMyc. This work is supportedfor binding, and sequenced as described.
by National Institutes of Health grants CA57345 and CA62924. B. V.
is an investigator of the Howard Hughes Medical Institute. K. W. K.
Gel Electrophoretic Mobility Shift Assays received research funding from Genzyme Molecular Oncology (Gen-
DNA-binding assays supplemented with Poly dIdC (6 mg/ml) were zyme). Under a licensing agreement between the Johns Hopkins
performed essentially as described (Zawel et al., 1998). For binding University and Genzyme, the SAGE technology was licensed to
to PCR products derived from in vitro site selections, 1.0±1.5 mg of Genzyme, and K. W. K. and B. V. are entitled to a share of royalties
protein and 50 ng of DNA were used. For competitions, a 100-fold received by the University from sales of the licensed technology.
excess of unlabeled probe was used. For GEMSA with GST fusion The SAGE technology is freely available to academia for research
proteins, 0.3±0.5 mg of fusion protein and 0.5 ng of 32P kinase labeled purposes. K. W. K. and B. V. are consultants to Genzyme. The
(z106 dpm) DNA were used. The probes for Tcf-4 binding were as pre- University and researchers (K. W. K. and B. V.) own Genzyme stock,
viously reported (Korinek et al., 1997). For GEMSA with in vitro trans- which is subject to certain restrictions under University policy. The
lated proteins, 0.1 to 0.2 ml of programmed lysate and 32P-labeled terms of this arrangement are being managed by the University in
probe (z106 dpm) was used. The DRE probe was formed by anneal- accordance with its conflict of interest policies.
ing 59-GCGTGAGCGCTCACAGGTCAATTCG-39 and 59-CCGAATT
GACCTGTGAGCGCTCACG-39. The ACO probe was formed by
Received May 7, 1999; revised September 27, 1999.
annealing 59-GCGGACCAGGACAAAGGTCACGTTC-39 and 59-CGA
ACGTGACCTTTGTCCTGGTCCG-39.
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